Tenderwize
Zurück zur Suche

Open House Contract for Peginterferon beta 1a

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2028 · 706 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 20 - Peginterferon beta 1a

56/100

Opportunity Score

Needs reviewHigh complexity
SuppliesOpen
Warum diese Bewertung?

Chance

56 / 100

Komplexität

68 / 100

Risikofaktoren

Offers/contracts cannot be submitted through the e-procurement portal; the notice says this is technically not possible...

Only pharmaceutical undertakings meeting AMG and seat/authorisation conditions may contract.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Conclude non-exclusive discount agreements for Peginterferon beta 1a under § 130a Abs. 8 SGB V.
  • Provide pharmaceutical products for nationwide performance in Germany.
Vollständige Zusammenfassung anzeigen

This is a German Open House supply arrangement by Techniker Krankenkasse for the active substance Peginterferon beta 1a (CPV 33600000 Pharmaceutical products). It is not an exclusive award procedure: all pharmaceutical undertakings meeting the stated conditions may enter into the contract on uniform terms. The contract term is up to 24 months from 01.08.2026 and ends no later than 31.07.2028, with earlier automatic termination if patent/market exclusivity ends. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post. No contract value is stated.

Risiken

Offers/contracts cannot be submitted through the e-procurement portal; the notice says this is technically not possible...

Only pharmaceutical undertakings meeting AMG and seat/authorisation conditions may contract.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG for the offered medicine(s).
  • Applicant must have its registered seat in the scope of the AMG, another EU Member State, or another EEA state.
  • Applicant must have a valid authorisation for the contract medicine or otherwise be entitled to market it in its own name.

Zuschlagskriterien

Lot 1

No substantive award criteria stated; form-only criterion in an Open House procedure.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Contract for Peginterferon beta 1a

Open House supply arrangement for Peginterferon beta 1a. The notice indicates nationwide performance in Germany. Contract terms are uniform and non-exclusive; no individual negotiations are conducted. The lot information is taken from structured data and XML notice.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Jul 2026 - Jul 2028

Kategorie

Pharmaceutical products

Zuschlagskriterien

No substantive award criteria stated; form-only criterion in an Open House procedure.

Frist

Deadline Jul 30, 2028

Vergabedetails

Veröffentlichungsdatum
31 May 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
372206-2026

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3